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Serum levels of miR-126 and miR-
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Several microRNAs (miRNAs) have been linked to chronic kidney disease (CKD) mortality, 
cardiovascular (CV) complications and kidney disease progression. However, their association with 
clinical outcomes remains poorly evaluated. We used real-time qPCR to measure serum levels of 
miR-126 and miR-223 in a large cohort of 601 CKD patients (CKD stage G1 to G5 patients or on renal 
replacement therapy – CKD G5D) from Ghent University Hospital and 31 healthy controls. All-cause 
mortality and cardiovascular and renal events were registered as endpoints over a 6 year follow-up 
period. miR-126 levels were significantly lower from CKD stage G2 on, compared to controls. The serum 
levels of miR-223 were significantly lower from CKD stage G3B on. When considering overall mortality, 
patients with levels of either miR-126 or miR-223 below the median had a lower survival rate. Similar 
results were observed for CV and renal events. The observed link between the two miRNAs’ seric levels 
and mortality, cardiovascular events or renal events in CKD appears to depend on eGFR. However, this 
does not preclude their potential role in the pathophysiology of CKD. In conclusion, CKD is associated 
with a decrease in circulating miR-223 and miR-126 levels.
Chronic kidney disease (CKD) is a major public health burden worldwide. This condition, and end-stage kidney 
disease in particular, is frequently associated with disorders of mineral and bone metabolism (CKD-MBD), and 
an increased cardiovascular risk in which progressive vascular calcification leads to a high cardiovascular mor-
tality rate1,2. The identification of prognostic biomarkers is therefore of the utmost relevance to CKD patients.
MicroRNAs (miRNAs) are short, single-stranded, non-coding RNAs that downregulate gene expres-
sion through translational repression or degradation of messenger RNA (mRNA) by binding to the mRNA’s 
3’-untranslated region3. miRNAs are highly conserved; the first miRNA was discovered in 1993 in Caenorhabditis 
elegans and the first human miRNAs were identified in 20004. About 3000 miRNAs have now been identified in 
the human genome3. Their biogenesis and mode of action have been extensively reviewed elsewhere5.
Dysregulation of miRNAs has been linked to the pathophysiology of many diseases, including kidney and 
cardiovascular diseases5–7. Our team reported that miR-126 and -223 levels were altered in the aortic wall and 
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serum in murine models of CKD8, and in the microcirculation of the brain of CKD mice9. Human targets of these 
miRNAs are shown in Supplementary Table 1.
miR-223 is considered to be a hematopoietic factor10 with a preponderant role in granulopoiesis11,12. It reg-
ulates cholesterol homeostasis and cardiac glucose metabolism, but it is also known to be an onco-miR13–15. In 
vascular disease, circulating miR-223 is able to penetrate the vascular smooth muscle cells (VSMCs) and act as an 
endocrine signal to regulate cell proliferation, migration and apoptosis16,17. In vitro, exposure of human VSMCs 
to pathological levels of inorganic phosphate (Pi) increases miR-223 expression as well as cell migration18. Finally, 
Ulbing et al. reported in a limited cohort of 140 patients, in CKD stages G3 to G5 or after kidney transplantation, 
that expression levels of miR-223-3p were lower in stage G4 and G5 CKD patients than in healthy controls19.
miR-126 is a pro-angiogenic miRNA present in endothelial cells20, and is highly expressed in vessels21. This 
miRNA has an important role in vascular dysfunction, since it enhances endothelial proliferation and endothe-
lialization of large vessels, which in turn attenuates atherosclerosis. In a murine model of CKD, miR-126 is over-
expressed in the aorta, along with the upregulation of SDF-18, a chemokine protein playing an important role 
in angiogenesis recruiting endothelial progenitor cells from the bone marrow. During tissue repair, in a mouse 
model of atherosclerosis, endothelial cells release miR-126 in apoptotic bodies, inducing SDF-1-dependent vascu-
lar repair22. Furthermore, miR-126 overexpression in bone marrow cells has recently been shown to promote vas-
cular integrity following kidney injury by contributing to the recovery of the kidney microvasculature23. Plasma 
levels of miR-126 are abnormally low in type 2 diabetes24, and low plasma levels are associated with a poor prog-
nosis in renal cell carcinoma25,26.
Recent studies have shown that miRNAs in blood27 and other body fluids28 are remarkably stable. They are 
protected from endogenous RNase activity by their binding to Argonaut proteins or their uptake in exosomes29 or 
microvesicles30. They are also transported by nucleophosmin 131, endothelial apoptotic bodies22 and high density 
lipoprotein (HDL)32. In view of the minimally invasive nature of blood and body fluid sampling and the stability 
of miRNAs, they may be useful as diagnostic and/or prognostic biomarkers.
The objectives of the present study were (i) to study the expression of circulating miR-126 and miR-223 in 
a cohort of 601 CKD patients and 31 healthy controls, and (ii) to evaluate the link between these miRNAs and 
cardiovascular and all-cause mortality. The secondary objective was to evaluate the association between the initial 
expression of miR-126 and miR-223 in serum and renal events and the decline of kidney function.
Results
Characteristics of the study population. A total of 632 subjects, 601 CKD patients and 31 healthy con-
trols were enrolled of which 628 were included in the final analysis (Fig. 1). Three CKD patients had missing 
data for the initial eGFR and, in one CKD patient, miRNA quantification in serum was impossible. The patients 
included in the analysis were divided into seven CKD groups, including patients on dialysis (22 patients on hemo-
dialysis and 13 patients on peritoneal dialysis) and healthy controls. The clinical and biochemical characteristics 
of the study population are summarized in Table 1 and Supplementary Table 2.
The median age was 64 years, 58.1% of the participants were male, 29% had diabetes mellitus, and 85.5% 
had hypertension. The groups differed with regard to age; controls, CKD G1 and G2 groups being significantly 
younger than CKD G4 and G5 groups. There were no statistically significant intergroup differences in gender or 
ethnicity. The mean arterial pressure was higher in the CKD G2 to G5 groups than in the other groups. Prevalence 
of diabetes was higher in the CKD G3B, CKD G4 and CKD G5 groups.
We observed statistically significant intergroup differences for serum phosphate, C-reactive protein (CRP), 
hemoglobin, glucose and lipid parameters and percentage of patients with significant proteinuria (>200 mg/L) 
(Supplementary Table 2).
Relationship between eGFR and miRNA baseline levels. The two miRNAs were detected in all sam-
ples. The serum levels of miR-126 and miR-223 over the course of CKD are summarized in Fig. 2.
The serum levels of miR-223 were significantly lower in the CKD G3B, CKD G4, CKD G5 and CKD G5D 
groups than in the healthy controls and the CKD G1 and CKD G3A groups. There were no statistically significant 
differences between the control group on one hand, and the CKD G1, CKD G2, and CKD G3A groups on the 
other.
When compared with controls, serum levels of miR-126 were significantly lower in the CKD G2, CKD G3A, 
CKD G3B, CKD G4, CKD G5 and CKD G5D groups but not in the CKD G1 group.
Figure 1. Study flow chart.
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n
Cohort Healthy CKD G1 CKD G2 CKD G3A CKD G3B CKD G4 CKD G5 CKD G5D
P value*628 31 65 88 120 158 108 23 35
Age, years 64 [49–74] 30 [25–58]¥ 38 [28–50] 54 [43–62] 66 [56–73] 71 [64–78] 73 [63–81] 72 [57–78] 66 [62–75] p < 0.05
Male, n (%) 365 (58) 13 (42) 32 (49) 50 (57) 68 (57) 96 (61) 72 (67) 11 (48) 23 (66) p = 0.26
Caucasian, n (%) 619 (99) 31 (100) 63 (97) 85 (97) 118 (98) 158 (100) 106 (98) 23 (100) 35 (100) p = 0.36
BMI, kg/m² 27 [23–31] 22 [20–23]¥ 25 [22–28] 27 [23–30] 27 [24–31] 29 [25–32] 28 [24–32] 26 [24–29] 26 [23–32] p < 0.05








[91–112] 92 [76–97] p < 0.05
Hypertension, n (%) 537 (86) 4 (13)¥ 48 (73) 71 (81) 110 (92) 153 (97) 106 (98) 22 (96) 23 (66) p < 0.05
Diabetes, n (%) 182 (29) 0 (0)¥ 9 (14) 21 (24) 28 (23) 65 (41) 42 (39) 9 (39) 8 (3) p < 0.05
Cardiovascular history, n (%) 53 (9) 0 (0)¥ 1 (2) 4 (5) 6 (5) 20 (13) 18 (17) 2 (9) 2 (6) p < 0.05
Etiology, n (%) n = 597
Nephroangiosclerosis 105 (17.5) 1 (2) 10 (11) 26 (22) 31 (20) 29 (27) 4 (17) 4 (11)
Diabetic nephropathy 93 (15.5) 4 (6) 9 (10) 11 (9) 42 (27) 20 (18) 2 (9) 5 (14)
ADPKD/Alport 41 (7) 8 (12) 12 (14) 7 (6) 6 (4) 4 (4) 2 (9) 2 (6)
Unique kidney 48 (8) 1 (2) 8 (9) 14 (12) 14 (9) 10 (9) 1 (4) 0 (0)
Lupus/vasculitis 39 (6.5) 14 (21) 9 (10) 10 (8) 4 (2) 1 (1) 1 (4) 0 (0)
Membranous nephropathy 8 (1) 0 (0) 4 (5) 2 (2) 1 (1) 1 (1) 0 (0) 0 (0)
IgA nephropathy 27 (4.5) 9 (14) 4 (5) 4 (3) 4 (2) 5 (5) 1 (4) 0 (0)
Urologic/reflux nephropathy 17 (3) 1 (2) 3 (3) 3 (3) 5 (3) 1 (1) 2 (9) 2 (6)
Tubulo-interstitial nephritis 40 (7) 6 (9) 3 (3) 11 (9) 5 (3) 8 (7) 4 (17) 2 (6)
Other glomerulonephritis 39 (6.5) 10 (15) 8 (9) 2 (2) 7 (4) 5 (5) 1 (4) 6 (17)
Renovascular nephropathy 10 (2) 2 (3) 1 (1) 0 (0) 4 (2) 3 (3) 0 (0) 0 (0)
Non-recovery from AKI 18 (3) 1 (2) 5 (6) 4 (3) 7 (4) 1 (1) 1 (4) 0 (0)
Toxic 33 (5.5) 0 (0) 2 (2) 10 (8) 11 (7) 9 (8) 1 (4) 0 (0)
Other or unknown 79 (13) 8 (12) 10 (11) 16 (13) 17 (11) 11 (10) 3 (13) 14 (40)
Medications, n (%)
ACEIs and/or ARBs 401 (64) 2 (6.5)¥ 43 (66) 57 (65) 84 (70) 111 (70) 78 (72) 13 (56) 13 (37) p < 0.05
Diuretics 243 (39) 3 (9.7)¥ 12 (18) 30 (34) 37 (31) 74 (47) 66 (61) 12 (52) 9 (26) p < 0.05
Calcium channel blockers 226 (36) 1 (3.2)¥ 10 (15) 24 (27) 44 (37) 74 (47) 56 (52) 11 (48) 6 (17) p < 0.05
Beta-blockers 280 (45) 2 (6.5)¥ 9 (14) 22 (25) 60 (50) 100 (63) 70 (65) 6 (26) 11 (31) p < 0.05
Other antihypertensive drugs 83 (13) 0 (0.0)¥ 2 (3) 60 (7) 12 (10) 28 (18) 25 (23) 6 (26) 4 (11) p < 0.05
Statins 340 (54) 1 (3.2)¥ 18 (28) 39 (44) 68 (57) 112 (71) 76 (70) 16 (70) 10 (29) p < 0.05
Table 1. Baseline characteristics of the cohort participants overall and by group (CKD patients, patients on 
RRT, and healthy controls). BMI: body mass index; ADPKD: autosomal dominant polycystic kidney disease; 
ACEI: angiotensin-converting-enzyme inhibitor; ARB: angiotensin II receptor blocker. Continuous variables 
are expressed as the median [IQR] and binary variables are expressed as the number (%). *The p value is for the 
comparison between CKD groups. Healthy controls vs CKD patients: ¥p < 0.001.
Figure 2. Relative expression (serum levels) of miRNAs in healthy controls, patients at different CKD stages, 
and patients on RRT. (A) Serum levels of miR-223. (B) Serum levels of miR-126. Data are shown as the median 
with box and whisker plots, including the 10th and 90th percentiles. *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001 (in a Mann-Whitney test).
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The correlation between serum miR-126 and miR-223 levels in the cohort is presented in Supplementary 
Figure 1 and is statistically significant. Serum levels of miR-126 and miR-223 were the same whatever dialysis 
technique (Supplementary Figure 2). It should be noted that the exogenous control used here (Cel-miR-39) had 
a similar Cq for all groups (Supplementary Figure 3).
Association of miR-126 and miR-223 with clinical and laboratory parameters. The results of lin-
ear regression analysis between miR-126 or miR-223 and baseline clinical and laboratory parameters are pre-
sented in Table 2.
A multiple regression analysis was used to assess the relationship between miR-223 and the parameters sig-
nificantly associated with miRNA expression in a univariate analysis. Parameters independently associated with 
miR-223 levels were the leukocyte count, eGFR, hemoglobin and sex (Supplementary Table 3).
Similarly, we used a multiple linear regression model of the entire cohort that included the variables signif-
icantly associated with miR-126 expression in univariate analysis; only eGFR, platelet count, hemoglobin level, 
and age were independently associated with serum miR-126 levels (Supplementary Table 3).
All-cause mortality and cardiovascular outcomes. Overall, during a median follow-up period of 1948 
days [1630–2146], 173 patients experienced cardiovascular events and 150 died (Table 3). Infection accounted for 
25 deaths, malignant disease for 24, and cardiovascular events for 29 deaths (Table 3). Twelve patients were lost to 
follow-up. When considering all-cause mortality, patients with levels of miR-223 and miR-126 below the median 
had a lower survival rate (Fig. 3A and C). However, the associations between both miRNA levels and overall 
mortality were no longer significant after adjustment for baseline eGFR (Supplementary Table 4). To confirm 
this result, we performed a power analysis. We assume a one-sided adjusted alpha risk of 2.5% (two miRNA were 
studied), a power of 80% and a correlation coefficient of 0.35 between eGFR and each miRNA. With the latter 
hypotheses, 150 deaths could permit the detection of a HR = 1.63 between the two groups defined by the median 
miRNA. An HR around 1.50 is realistic for a superiority time-to-event trial, therefore our study had enough sta-
tistical power to compared overall survival according to miRNA. Sensitivity analysis using Cox models adjusted 
for each CKD stage or a model with the eGFR*miR interaction or combining both miRNAs levels did not reveal 
any significant associations between miRNA levels and mortality after adjustment for eGFR baseline either (data 
not shown). When we focused more specifically on cardiovascular mortality, there was no significant association 
with miRNA levels after adjustment for baseline eGFR (Supplementary Table 5). When considering CV events, 
Parameters
miR-223 miR-126
ρ p ρ p
Age (n = 628) −0.21 p < 0.0001 −0.28 p < 0.0001
Sex (ref:female) (n = 628) 0.15 p = 0.0001 0.01 p = 0.78
Hypertension (n = 627) −0.05 p = 0.19 −0.18 p < 0.0001
MAP (n = 627) −0.02 p = 0.60 −0.02 p = 0.66
BMI (n = 625) −0.10 p = 0.009 −0.13 p = 0.0008
Diabetes (n = 628) −0.08 p = 0.04 −0.09 p = 0.03
CRP (n = 591) −0.03 p = 0.43 −0.04 p = 0.28
Serum Creatinine (n = 562) −0.31 p < 0.0001 −0.23 p < 0.0001
eGFR (n = 562) 0.30 p < 0.0001 0.26 p < 0.0001
Urea (n = 549) −0.29 p < 0.0001 −0.25 p < 0.0001
Calcium (n = 552) 0.09 p = 0.03 −0.02 p = 0.68
Phosphate (n = 548) −0.09 p = 0.04 −0.17 p < 0.0001
PTH (n = 438) −0.26 p < 0.0001 −0.23 p < 0.0001
25-OH-D (n = 330) −0.08 p = 0.17 −0.09 p = 0.12
Proteinuria (n = 524) −0.07 p = 0.19 −0.10 p = 0.02
Hemoglobin (n = 583) 0.29 p < 0.0001 0.24 p < 0.0001
Leukocyte count (n = 581) 0.31 p < 0.0001 0.04 p = 0.28
Platelet count (n = 580) 0.24 p < 0.0001 0.18 p < 0.0001
Glucose (n = 537) −0.04 p = 0.31 −0.08 p = 0.08
Triglycerides (n = 518) −0.03 p = 0.44 0.01 p = 0.91
Cholesterol (n = 527) 0.16 p = 0.0002 0.14 p = 0.0009
HDL (n = 440) 0.08 p = 0.11 0.06 p = 0.22
LDL (n = 422) 0.15 p = 0.002 0.13 p = 0.006
Table 2. Association of miR-223 and miR-126 with clinical and laboratory parameters (Spearman’s rank 
correlation coefficient, ρ). MAP: mean arterial pressure; BMI: body mass index; CRP: C-reactive protein; eGFR: 
estimated glomerular filtration rate; PTH: parathyroid hormone; 25-OH-D: 25-hydroxy vitamin D; HDL: high-
density lipoprotein; LDL: low-density lipoprotein. The healthy control group was excluded from the analysis of 
laboratory characteristics and the RRT group was excluded for non-interpretable laboratory parameters (serum 
calcium, phosphate, urea, eGFR and proteinuria), due to the dialysis.
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patients with below-median levels of miR-223 and miR-126 had a lower CV event rate (Fig. 3B and D). However, 
theses associations were no longer significant after adjustment for baseline eGFR (Supplementary Table 6).
We further divided CV events into atheromatous and non-atheromatous events and performed the statistical 
analysis for each in relation with the miRNA levels. The results were globally similar, but it should be pointed out 
that in univariate analysis, miR-223 was associated with non-atheromatous events, but not with atheromatous 
events (Supplementary Tables 7 and 8).
n
CKD Cohort CKD G1 CKD G2 CKD G3A CKD G3B CKD G4 CKD G5 CKD G5D
p597 65 88 120 158 108 23 35














[1135–2157] p = 0.006
Alive, n (%) 447 (75) 64 (98) 79 (90) 99 (82) 112 (71) 58 (54) 13 (56) 22 (63) p < 0.0001
Primary outcome, n (%) 250 (42) 4 (6) 16 (18) 43 (36) 85 (54) 65 (60) 14 (61) 23 (66) p < 0.0001
Death, n (%) 150 (25) 1 (2) 9 (10) 21 (17) 46 (29) 50 (46) 10 (43) 13 (37) p < 0.0001
   infection 25 (4) 1 (2) 0 (0) 3 (3) 6 (4) 11 (10) 1 (4) 3 (9)
   malignancy 24 (4) 0 (0) 0 (0) 6 (5) 9 (6) 7 (6) 1 (4) 1 (3)
   cardiovascular cause 29 (5) 0 (0) 3 (3) 3 (3) 11 (7) 9 (8) 1 (4) 2 (6)
   refuse dialysis 4 (1) 0 (0) 0 (0) 0 (0) 0 (0) 2 (2) 0 (0) 2 (6)
   undetermined 68 (11) 0 (0) 6 (7) 9 (8) 20 (13) 21 (19) 7 (30) 5 (14)
Cardiovascular events, n (%) 173 (29) 3 (5) 11 (12) 33 (27) 63 (40) 39 (36) 8 (35) 16 (46) p < 0.0001
   atheromatous 119 (20) 3 (5) 6 (7) 27 (22) 41 (26) 26 (24) 6 (26) 10 (29)
   non-atheromatous 71 (12) 0 (0) 6 (7) 9 (7) 26 (16) 20 (19) 3 (13) 7 (20)
Secondary outcome, n (%)* 83 (15) 0 (0) 7 (8) 6 (5) 18 (11) 38 (35) 14 (61) n.a. p < 0.0001
Renal events, n (%) 57 (10) 0 (0) 3 (3) 1 (1) 7 (4) 32 (30) 14 (61) n.a. p < 0.0001
   dialysis 49 (9) 3 (3) 1 (1) 7 7 (4) 27 (25) 11 (48) p < 0.0001
   transplant 16 (3) 0 (0) 0 (0) 0 (0) 6 (6) 5 (22) p < 0.0001
Renal impairment, n (%) 45 (8) 0 (0) 6 (7) 6 (5) 13 (8) 18 (17) 2 (9) n.a. p < 0.0001
Table 3. Outcomes in the CKD cohort and each CKD stage group. n.a.: not applicable. *n = 562 (excluding 
CKD 5D). Continuous variables are expressed as the median [IQR] and binary variables are expressed as the 
number (%).
Figure 3. Unadjusted survival curves for primary outcomes for participants with above-median and below-
median serum miR-223 (A and B) or miR-126 (C and D) levels (Log-rank test).
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Renal outcomes. Among the 562 non-dialysis CKD patients, 57 developed need for renal replacement ther-
apy, either dialysis or transplantation during follow-up (Table 3) and 45 experienced an accelerated loss of renal 
function (defined as a doubling of the serum creatinine level, or a reduction of eGFR by 30%, over two years). 
CKD patients stage G1 to G5 not yet on dialysis with above-median levels of miR-223 and miR-126 had a signif-
icantly better event-free survival rate (Fig. 4). However, the associations between both miRNA levels and renal 
events were no longer significant after adjustment for baseline eGFR (Supplementary Table 9).
After a median follow up of 737 days, among 458 patients with non-dialysis CKD, 134 patients were consid-
ered as fast progressors (an eGFR decrease of more than 3 mL/min/1.73 m²/year), 229 as non-progressors (an 
eGFR decrease of less than 1 mL/min/1.73 m²/year) and 95 as slow progressors (an eGFR decrease of between 1 
and 3 mL/min/1.73 m²/year). There was no difference between the three groups with regard to the serum levels of 
miR-223 and miR-126 (Supplementary Figure 4).
Discussion
The present study demonstrated a statistically significant decrease in circulating miR-126 and miR-223 levels in 
patients with more severe stages of CKD. Levels of miR-126 were independently associated with eGFR but also 
with hemoglobin level, platelet count, and age. The circulating level of miR-223 was independently associated with 
leukocyte count and hemoglobin level, sex, and eGFR. We did not find an independent correlation between any 
studied miRNA and the serum level of CRP or with diabetes. The event-free survival rate was better in patients 
with higher circulating miRNA levels. After adjustment for eGFR, neither miR-126 nor miR-223 level were prog-
nostic markers of all-cause mortality, cardiovascular events or renal events. We did not observe an association 
between the initial circulating levels of miR-126 and miR-223 and the decline of kidney function over two years.
Glomerular filtration rate estimated from the serum level of creatinine currently remains the most convenient 
marker of renal function for everyday practice and large epidemiologic studies. Albuminuria, proteinuria and 
seric urea levels are useful indicators of renal function when normalized for urinary creatinine. They are however 
not very sensitive when used to detect the first stages of CKD33. Several other markers have been assessed for 
their predictive value of mortality, cardiovascular (CV) complications and kidney disease progression without 
success34–40. miRNAs have recently attracted attention as biomarker candidates to assess the severity and/or the 
etiologies of kidney disease41,42. One of the main advantages of miRNAs is their seric stability, which makes 
them suitable as a non-invasive biomarker27. One can thus hope that these small RNAs could prove to be reliable 
enough to be useful in potential clinical practice43,44.
Quantitative PCR is a technique commonly used for accurate quantification of miRNA levels in blood samples 
and transplantable in a clinical laboratory. In quantitative PCR, it is important to choose an adequate control 
gene, especially as miRNA levels are low in the circulation. Some teams have chosen to use small endogenous 
RNAs, such as U6, to normalize circulating miRNAs levels but the results have proven to be unreliable due to 
marked variability of the expression of these RNAs according to pathological conditions45. An emerging consen-
sus is now to spike-in in the blood sample before extraction a given quantity of exogenous miRNA (such as the 
synthetic Caenorhabditis elegans miR-39)46,47.
Figure 4. Unadjusted survival curves for secondary outcomes for participants with above-median and below-
median serum miR-223 (A and B) or miR-126 (C and D) levels (Log-rank test).
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Several teams have shown that the overall expression of miRNAs blood concentration diminishes as CKD 
advances48,49. In a cohort of 90 CKD patients (stages G3 to G5D) Chen et al. published that miR-125b, miR-145 
and miR-155 levels decline as CKD progresses50. The blood levels of cardiac miRNAs also seems to decline with 
eGFR51. In the present study, we observed a decrease in serum levels of miR-126 and miR-223 as renal function 
declined. However, proof that kidney function affects miRNA levels in plasma and urine is sparse and sometimes 
contradictory. Some studies were interested in the possible accumulation of RNases known in renal failure52 
which could increase degradation of circulating miRNAs in the plasma, but these are protected in particular 
by exosomes and Argonaut proteins. In the present study, serum RNA levels after extraction did not differ as a 
function of the CKD stage (data not shown) – suggesting that there is no degradation, in line with other reports50.
Over the last years, we studied the role of uremic toxins in in vitro models of osteoclastogenesis and vascular 
calcification.5 We highlighted the roles of miR-223 and miR-126 in the trans-differentiation of VSMCs to an 
osteoblastic phenotype linked with vascular calcification18,53. We confirmed this finding in vivo by showing that 
miR-126 and miR-223 expression was enhanced in aortas of murine CKD models, while their serum levels were 
decreased8 which may indicate an accumulation of these two miRNAs in vascular walls. In 2016, Ulbing et al. 
found a decrease of seric levels of miR-223 in CKD patients that was alleviated after renal graft19. In our large 
cohort covering the whole spectrum of CKD, we also observed low expression - from stage G3B onwards for miR-
223, and from stage G2 onwards for miR-126.
In the present study, the eGFR was the clinical feature most strongly correlated with miRNA concentration 
(apart from leukocyte count for miR-223 and age for miR-126). The observed associations between the miRNA 
level and the other features of severe kidney failure (e.g. hyperparathyroidism and hyperphosphatemia) in uni-
variate analyses were mediated by the impairment in glomerular filtration. There was a good degree of correlation 
between miR-223 level on one hand and sex, leukocyte count, platelet count, and blood hemoglobin and cho-
lesterol levels on the other. The relationship with blood cell counts has already been reported, and is related to 
the involvement of miR-223 in hematopoiesis and its strong expression in granulocytes, platelets and red blood 
cells10–12,54–56. miR-223 has been involved before in cholesterol homeostasis57, and we found accordingly a corre-
lation with cholesterol levels using univariate analysis. In our multivariate analysis, only loss of kidney function, a 
low leukocyte count, a low hemoglobin level, and male sex were associated with low circulating levels of miR-223. 
Although miR-223 is often considered to be a marker of inflammation58, levels were not correlated with serum 
CRP. In univariate analyses, the circulating level of miR-126 was notably correlated with age, hemoglobin and 
cholesterol levels, and platelet count. The correlation with cholesterol and LDL has already been reported but 
the underlying mechanism have not yet been identified59. In our multivariate analysis, miR-126 level was inde-
pendently associated with eGFR, platelet count, hemoglobin level, and age. The correlations with hemoglobin 
and eGFR have previously been described60, as have the correlations with platelet count61 and age62. Grabher et al. 
demonstrated that miR-126 regulates the proto-oncogene c-Myb during hematopoiesis63.
According to our results, miR-126 and miR-223 cannot be used as prognostic markers because of their 
eGFR-related variability. Indeed, miR-126 and miR-223 levels were not independently associated with poor sur-
vival after adjustment for eGFR. The results were similar for mortality, cardiovascular events, and renal events 
– none of which were predictive of a further decline in eGFR.
The present study is the first having investigated these two miRNAs as potential biomarkers in CKD. Its 
strengths include the large study population and the availability of data over the full range of CKD stages includ-
ing a group of controls without CKD, enabling stratification by CKD stage. We also assessed a number of impor-
tant, potentially confounding routine laboratory parameters with a long term follow-up. We studied for the first 
time in a large CKD cohort the impact of serum miRNA levels on hard outcomes. However, our study also has 
several limitations. Estimated GFR was used in the analysis, instead of the more accurate direct measurement 
of GFR. Nevertheless, we used the CKD-EPI formula which estimates GFR more accurately compared to other 
widely-used formulas. Another limitation is that miRNA levels were only measured at the baseline examination.
In conclusion, lower circulating levels of miR-126 and miR-223 were associated with lower eGFR in a cohort 
of patients with CKD at different stages. The observed link between the two miRNAs’ seric levels and mortality, 
cardiovascular events or renal events in CKD appears to depend on eGFR. However, this does not preclude their 
potential role in the pathophysiology of CKD, which will need further evaluation.
Methods
The study population. A total of 601 patients with CKD stages G1 to G5 (as defined by the Kidney Disease 
Outcomes Quality Initiative guidelines (KDOQI)) or on renal replacement therapy (RRT: hemodialysis or peri-
toneal dialysis) and 31 healthy controls were included in this single-center study at the outpatient clinic of the 
Section of Nephrology, Ghent University Hospital (Ghent, Belgium). Inclusion took place between January 2011 
and January 2014. The exclusion criteria were pregnancy, age under 18, active infection, active malignancy or 
history of transplantation. Outcome parameters were monitored until June 2017 (for up to 6 years). Patients with 
CKD were categorized into subgroups according to their estimated glomerular filtration rate (eGFR), using the 
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) – creatinine equation, as recommended by the 
KDOQI. Eight subgroups were compared, including six CKD subgroups not on dialysis (eGFR: over 90, 60–89, 
45–59, 30–44, 15–29, and below 15 ml/min/1.73 m²), one CKD subgroup on RRT (stage G5D), and healthy 
controls. Hypertension was defined as a systolic blood pressure >140 mmHg and/or a diastolic blood pressure 
>90 mmHg, or the need for anti-hypertensive medication.
Ethical approval. This study was approved by the local ethical committee at Ghent University Hospital. 
Written informed consent was obtained from all participants. The study complied with the tenets of the 
Declaration of Helsinki and its amendments.
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Blood samples. A sample of venous blood was collected in Venosafe serum (Terumo Europe, Leuven, 
Belgium) tubes. The blood was left to coagulate for 30 minutes on the bench and was then centrifuged at 2,095 × g 
for 10 min at room temperature (RT). The serum samples were divided into 500 μL aliquots on ice and stored at 
−80 °C until batch analysis.
RNA extraction. Total RNA was extracted with the miRNeasy Serum/Plasma kit (Qiagen, Germany), 
according to the manufacturer’s instructions. Stored serum was thawed on ice and shaken. Next, 1000 μl of 
Qiazol lysis reagent was added to 200 μl of serum and incubated at RT for 5 min. A fixed amount of synthetic 
Caenorhabditis elegans miR-39 (3.5 µL of Cel-miR-39 at 1.6 × 108 copies/µL, i.e. 1 fmol) was added as an internal 
control. Next, 200 μl of chloroform was added, and the sample was shaken for 15 s. After incubation for 3 min 
at room temperature, the samples were centrifuged for 15 min at 16,100 × g at 4 °C. The upper aqueous phase 
(approximately 700 μl) was transferred to a new tube, and 1000 μl of 100% ethanol was added. The RNA was iso-
lated with a miRNeasy MinElute spin column and solutions (Qiagen, Germany), eluted from the columns with 
14 μl RNase-free water, and stored at −80 °C.
The purity and concentration of the isolated RNA were determined using a NanoDrop spectrophotometer 
(Thermo Fisher Scientific, USA).
Reverse transcription. Isolated RNA was reverse-transcribed into complementary DNA using TaqMan 
miRNA-specific primers and the TaqMan microRNA reverse transcription kit (Applied Biosystems, USA) on 
ice. Each well contained the following mixture: 2.8 μL of RNase-free water, 1.5 μL of 10X RT buffer, 1.5 μL of 
dNTP mix (10 mM), 0.2 μL of RNase inhibitor (20 U/μL), 1 μL of MultiScribe® RT enzyme ΜL (50 U/µL), 3 μL 
of 5X primers (i.e. for miR-223, miR-126 or Cel-miR-39) and 5 μL of RNA 5 ng/μL (i.e. 25 ng). The Eppendorf 
Mastercycler® thermocycler was used to incubate the samples at 16 °C for 30 min, at 42 °C for 30 min and then at 
85 °C for 5 min. The cDNA samples were then stored at −20 °C.
Quantification of serum miRNA levels. Serum levels of miR-223 and miR-126 were quantified using 
TaqMan qRT-PCR. cDNA (2.4 μL) was amplified using 18 μL of SsoAdvanced™ Universal Probes Supermix 
(Bio-Rad Laboratories, USA), 1.8 μL of 20X Primers and 13.8 μL of RNase-free water, in a final volume of 36 μL. All 
reactions and analyses were performed in triplicate on CFX Connect (Bio-Rad) according to the following proto-
col: incubation at 95 °C for 30 seconds, then 40 cycles of 15 seconds at 95 °C, and incubation at 60 °C for 30 seconds. 
Exogenously added Caenorhabditis elegans-miR-39 (Cel-miR-39) was used as a spiked-in normalization control. The 
relative expression levels of miR-223 and miR-126 were calculated using the 2-ΔCq method, where ΔCq = Cq (miR-
223 or miR-126) − Cq (cel-miR-39). The maximum accepted coefficient of variation for intra-assay replicates was set 
to 5%. All experiments were performed by the same person (O.F.) who was blinded for the outcomes, to avoid bias.
Outcomes. All the outcomes were collected prospectively. The primary outcomes were all-cause mortal-
ity, and cardiovascular events (fatal and non-fatal). Cardiovascular events were defined as atheromatous or 
non-atheromatous cardiovascular disease (CVD). Atheromatous CVD was defined as coronary artery disease 
(CAD), ischemic stroke or transient ischemic attack, peripheral arterial disease requiring a revascularization 
procedure or an amputation. Non atheromatous CVD was defined as heart failure in the absence of CAD, cardiac 
rhythm or conduction disorders, or aortic aneurysm.
Renal events were defined as progression towards RRT (dialysis or renal transplantation), or a doubling of 
the serum creatinine level, or a reduction of eGFR by 30%, over two years (according to the FDA criteria64). The 
CKD G5D group was excluded from the analysis of the renal events. The variation of eGFR between inclusion and 
end of renal follow-up (at one or two years of follow-up according to the patients) was calculated. We also stud-
ied miRNA levels in three strata: a decrease in the eGFR <1 mL/min/1.73 m²/year (non-progressors), 1–3 mL/
min/1.73 m²/year (slow progressors) or >3 mL/min/1.73 m²/year (fast progressors).
Statistical analyses. Patient characteristics and the relative expression levels of miR-223 and miR-126 are 
presented as median [interquartile range (IQR)] for continuous variables (because the data were not normally dis-
tributed except for hemoglobin) or as the number (frequency) for binary variables. Intergroup comparisons were 
performed using a Kruskal-Wallis test for continuous variables and a χ² test for binary variables. Comparisons 
between two groups were performed with a Mann-Whitney test. The relationships between patient characteristics 
and miRNA levels were explored using Spearman’s rank correlation tests. Multiple linear regression analyses were 
performed to investigate the association between clinical/laboratory parameters and the expression of miRNAs. 
The Kaplan-Meier survival curves were constructed to estimate overall mortality, cardiovascular and renal events 
by dividing the studied population according to the selected cut-off (the median level: 2.28 for miR-223 and 
0.09 for miR-126). The log-rank test was used to compare survival curves. Univariate and multivariate analyses 
of outcomes were performed by building a Cox proportional hazards model based on miRNA levels. Due to 
non-normal distribution, the data were log-transformed. The multivariate analysis included all the parameters 
with a p-value < 0.05 in the univariate analysis. In all the tests, the threshold for statistical significance was set to 
p < 0.05. Statistical analyses were performed using GraphPad Prism® software version 6 and SPSS® software ver-
sion 21. The power analysis was performed using package powerSurvEpi with software “RStudio software Version 
1.0.143 – © 2009–2016 RStudio (R.3.4.0 software)” as described previously65.
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